Address:Mount Sinai School of Medicine

Date updated: 6/09

Name:Steven J. Burakoff, M.D.

Address:Mount Sinai School of Medicine

The Tisch Cancer Institute

One Gustave L. Levy Place – Box 1079

C/o Hematology/Oncology Department

New York, NY 10029

Birth Place: New York, New York

Education:

1964 B.A.with Honors, Lehigh University, Bethlehem, Pennsylvania

1965 M.A.Queens College, Flushing, New York (Psychology)

1970 M.D.Albany Medical College, Albany, New York

1984 M.A.(hon.) Harvard University, Cambridge Massachusetts

Postdoctoral Training:

Internships and Residencies:

1970-71Medical Intern, New York Hospital-Cornell Medical Center, New York, New York

1971-73Medical Resident, New York Hospital-Cornell Medical Center

Clinical and Research Fellowships:

1973Fellow in Immunology, Rockefeller University, New York, New York

(Advisor: Dr. Henry Kunkel)

1973-76Research Fellow in Immunology, Harvard Medical School, Boston

(Advisor: Dr. Baruj Benacerraf)

Licensure and Certification:

1973Massachusetts

1973Diplomate, American Board of Internal Medicine

2001 New York State License 110740-1

Academic Appointments:

1976-77Instructor of Pathology, Harvard Medical School

1977-80Assistant Professor of Pathology, Harvard Medical School

1980-83Associate Professor of Pediatrics, Harvard Medical School

1983-00Professor of Pediatrics, Harvard Medical School

1995-00Ted Williams Senior Investigator, Dana-Farber Cancer Institute

1998-00Margaret M. Dyson Professor of Pediatrics, Harvard Medical School

2000-06Director, Skirball Institute of Biomolecular Medicine, New York University School of Medicine

2000-07Laura and Isaac Perlmutter Professor, New York University School of Medicine

2000-07Director, NYU Cancer Institute, New York University School of Medicine

2007-Director, The Tisch Cancer Institute, Mount Sinai School of Medicine

(formerly the Mount Sinai Cancer Institute)

2007-Professor of Medicine, Hematology and Medical Oncology

Mount Sinai School of Medicine

2009-Acting Chief, Division of Hematology and Medical Oncology,

Department of Medicine, Mount Sinai School of Medicine

2009-Lillian and Henry M. Stratton Professor of Cancer Medicine,

Mount Sinai School of Medicine

Hospital Appointments:

1978-79Junior Associate in Medicine, Peter Bent Brigham Hospital, Boston, Massachusetts

1980-00Associate in Medicine (Hematology-Oncology), Children's Hospital Medical Center, Boston, Massachusetts

1980-84Associate Physician, Dana-Farber Cancer Institute

1984-00Physician, Dana-Farber Cancer Institute

1985-00Chair, Department of Pediatric Oncology, Dana-Farber Cancer Institute

2000-06Director, Skirball Institute of Biomolecular Medicine New York University School of Medicine

2002-07Director, New York University Cancer Institute and Kaplan Comprehensive

Cancer Center

2007-Director, The Tisch Cancer Institute

2007-Professor of Medicine, Hematology and Medical Oncology

Mount Sinai School of Medicine

2009-Acting Chief, Division of Hematology and Medical Oncology,

Department of Medicine, Mount Sinai School of Medicine

Other Professional Positions and Major Visiting Appointments:

1979Visiting Professor, Centro de Investigacion y de Estudios Avanzados del Institute Politecnico Nacional, Mexico City, Mexico

1981-82Visiting Scientist, Weizmann Institute, Rehovot, Israel

1982-85U.S.- Japan National Cancer Institute Tumor Immunology Exchange Program

1988U.S. - Japan National Cancer Institute Tumor Immunology Exchange Program

Awards and Honors:

1980-85American Cancer Society Faculty Research Award

1982American Society of Clinical Investigation

1988Honored Speaker, Tohoku Medical Society, Japan

1992Alpha Omega Alpha

1992Alpha Omega Alpha Lecturer, Albany Medical College

1992David A. Talmadge Lecture, Colorado Allergy Society

1994Horizons in Biomedical Research Lecture, Cleveland Clinic Foundation

1995Association of American Physicians

1995Harvard Medical School Excellence in Mentoring Award

1995Ted Williams Senior Investigator, Dana-Farber Cancer Institute

1998Margaret M. Dyson Professor of Pediatrics, Harvard Medical School

2000Laura and Isaac Perlmutter Professor, New York University, School of Medicine

2001ISI Highly Cited Researcher (1980-2000)

2002Theobald Smith Alumni Lecture, Albany Medical College

2003Distinguished Alumnus 2003, Albany Medical College Alumni

2006Lynne Cohen Foundation Awardee

2009American Association of Immunologists Lifetime Achievement Award

Major Committee Assignments:

National and Regional

1979-83Member, Clinical Sciences Study Section, National Institutes of Health

1983-87Advisory Committee on Immunology and Immunotherapy American Cancer Society. Vice Chairman for 1986, Chairman for 1987.

1983-86Member, Program Committee, American Association of Immunologists, Cochairman for 1984 FASEB meeting, Chairman for l985 and 1986 FASEB meetings.

1988-92Member, Program Committee, American Association of Immunologists, liaison to Clinical Immunology Society

1989Cochairman, FASEB Conference: Cellular and molecular studies of bone marrow transplantation

1989-90NIAID Task Force on Immunology and Allergy

1992-95Member, Executive Committee, 1995 International Congress of Immunology; Chairman, Finance Committee

1993-98 Member, Scientific Affairs Subcommittee on Transplantation Biology, American Society of Hematology

1993-Member, External Advisory Committee, Division of Clinical Sciences,

Fred Hutchinson Cancer Institute

1994-95 Member, World AIDS Foundation

1994Member, Ad hoc Advisory Committee, Office of AIDS Research

1994-00Chairman, Biomedical Research Committee, The Medical Foundation

1994-00Member, Board of Directors, The Medical Foundation

1995-98Member, Finance Committee, American Association of Immunologists

1998-01Member, Finance Committee, Federation of Associations for Experimental Biology

1999-03Member, Publications Committee, American Assn. of Immunologists

2001-Member, Scientific Advisory Board, Cold Spring Harbor Laboratory Cancer Center

2002- Member, External Advisory Board, Baylor College of Medicine Cancer Center

2002-Member, External Advisory Board, University of Massachusetts Medical School Cancer Center

2003-Secretary-Treasurer, American Association of Immunologists

2003-Member, External Advisory Board, Albert Einstein College of Medicine

Cancer Center

2005-Member, External Advisory Board, St. Jude Research Hospital Cancer Center.

2006-External Advisory Board, Boston University School of Medicine Cancer Center

2006-Member, Nominating Committee, Association of American Cancer Institutes 2007- Member, Scientific Review Board, Starr Foundation Consortium.

2007-Member, American Cancer Society Council for Extramural Grants

2007-Damon Runyon Cancer Research Foundation, Board Member

Harvard Medical School

1984-86Co-director, Hybridomas in Biotechnology and Medicine. Postgraduate course, Harvard Medical School

1988-91Member, Faculty Fellowships Committee, Harvard Medical School

1988-00Member, Committee on Immunology, Harvard Medical School

1989-92Member, Subcommittee of Professors, Harvard Medical School

1992-93Member, Ad hoc Committee on Relations with Industry, Harvard Medical School

1995-00Member, Promotions and Appointment Committee, Harvard Medical School

1998-99Member, M.D./Ph.D. Program Review Committee, Harvard Medical School

1998-00Member, M.D./Ph.D. Committee, Harvard Medical School

Dana-Farber Cancer Institute

1980-81Member, Animal Care Committee, Dana-Farber Cancer Institute

1981-85Member, Biomedical Research Support Grant Committee, Dana-Farber Cancer Institute

1981-87Chairman, Animal Care Committee, Dana-Farber Cancer Institute

1994-00Faculty Council, Dana-Farber Cancer Institute

1995-99Promotion and Appointments Committee, Dana-Farber Cancer Institute

1995-00Executive Management Group, Dana-Farber Cancer Institute

1995-00Executive Committee for Research, Dana-Farber Cancer Institute

1996-00Board of Trustees, Dana-Farber Cancer Institute

1996-00Elected Member, Executive Committee, Board of Trustees, Dana-Farber Cancer Institute

1999-00Executive Committee, Dana-Farber/Harvard Cancer Center

New York University School of Medicine

2000-07Joint Planning Committee, NYU Cancer Institute

2000-07Dean’s Research Advisory Committee

2000-07Chair, Executive Management Committee, NYU Cancer Institute

2003-04Chair, Search Committee, Chair of Department of Pathology

2003-04Internal Advisory Committee, National Institute of Environmental Health Science Center

2004-07Internal Advisory Committee, Center for AIDS Research

2004-05Member, Dermatology Chair Search Committee

2004-05Dean’s Steering Committee on Budget

2005-07Member, Steering Committee, Liaison Committee on Medical Education (LCME)

2005-07Internal Advisory Committee, Clinical Research Training Program in

Translational Medicine

2006-07Member, Clinical Translational Science Award External Advisory

Committee.

2006-07Dean's Committee on Institutional Resources (DCIR), Research &

Education Subcommittee

2007-Adjunct Professor, Department of Pathology

Mount Sinai School of Medicine:

2007-Director of The Tisch Cancer Institute (formerly the Mount Sinai Cancer Institute)

2007-Professor of Medicine, Mount Sinai School of Medicine
2007-Professor of Oncological Sciences, Mount Sinai School of Medicine

2008-Advisory Board, Institute for Rationalized Medicine

2009:Search Committee, Chief of Pediatrics

2009:Search Committee, Chief of Hematology/Oncology

2009:Search Committee Director of the Genome-Based Research Center

Editorial Boards:

1979-81Associate Editor, Journal of Immunology

1981-85Section Editor for Tumor Immunology, Journal of Immunology

1981-Editor for Tumor Immunology, Immunologic Research

1983-96Editorial Board, Cellular Immunology

1985-87Editorial Board, Transplantation

1992-94Deputy Editor, Journal of Immunology

1993-96Editorial Board, Journal of Clinical Immunology

1995-01Editorial Board, Biology of Blood and Marrow Transplantation

Invited Speaker at Professional Meetings:

2006Second Joint American-Israeli Conference on Cancer, Jerusalem, Israel

June 28-30, 2006

Memberships, Offices and Committee Assignments in Professional Societies:

American Association of Immunologists

Transplantation Society

Clinical Immunology Society

American Society of Hematology

American Society of Clinical Investigation

Association of American Physicians

Molecular Medicine Society

American Society of Clinical Oncology

American Association for Cancer Research

Major Research Interests:

1. Cellular and molecular immunology

2. T cell activation and signal transduction

3. Transplantation immunology

Teaching Experience:

Harvard Medical School

1978-80Lecturer in Immunology and Immunopathology 700

1980Tutorial in Cellular Immunology

1985-00Immunology 321, Studies of T cell Activation.

1988Lecturer in Identity, Microbes and Defense.

1988Lecturer in Immunology 200, Basic Immunobiology.

1998-01Codirector in Immunology 212, Lymphocyte Signal Transduction.

1999-00Lecturer in Immunology 300, Signal Transduction in Immune Cells.

Advising Responsibilities:

Graduate Student Sponsor

Past:Harvard Medical School

1977-80Paul Billings, M.D., Ph.D.

1978-81Ofra Weinberger, Ph.D.

1982-89Michael Petrarca, Ph.D

1985-88Sheldon Ratnofsky, Ph.D

1985-88Barry Sleckman, M.D., Ph.D.

1987-90John Park, M.D., Ph.D.

1989-92William Hahn, M.D., Ph.D.

1990-94Tassie Collins, Ph.D.

1991-94David Fruman, Ph.D.

1992-97Kyungah K. Lee-Fruman, Ph.D.

1994-98Hanna Yoko Irie, M.D., Ph.D.

1995-01Michael Su, M.D., Ph.D.

1995-01Ruben Fragoso, M.D., Ph.D.

2002-07Saba Alzabin, Ph.D.

Graduate Student Sponsor

NYU School of Medicine

2003-Yi Cai

Industry Relations

1986-96Consultant, Genetics Institute, Cambridge, MA.

1989-08Scientific Advisory Board, Vertex Pharmaceuticals,

Cambridge, MA.

1990-95Consultant, Hoffman La Roche, Basel, Switzerland.

1990-96Consultant, Medical Science Partners, Boston, MA.

1995-00Consultant, Novartis, Basel, Switzerland.

1995,1996Consultant, Bristol Myers Squibb, Princeton, N.J.

1996-03Scientific Advisory Board, Pharmacopeia, Princeton, N.J.

2004-Board of Directors, Pharmacopeia, Pharmacopeia, Princeton,

Leadership Roles:

1982-94Chief of Immunology, Bone Marrow Transplant Unit, The Children's Hospital and Brigham and Women's Hospital

1982-95Director, Pediatric Oncology Research Program, Dana-Farber Cancer Institute

1985-00Chair, Department of Pediatric Oncology, Dana-Farber Cancer Institute

1996-00Member, Executive Committee for Research, Dana-Farber Cancer Institute

1996-00Member, Board of Trustees, Dana-Farber Cancer Institute

1996-00Member, Executive Committee of the Board of Trustees, Dana- Farber Cancer Institute

2000-07Director, Skirball Institute of Biomolecular Medicine, New York University School of Medicine

2000-07Director, NYU Cancer Institute and Kaplan Comprehensive Cancer Center, New York University School of Medicine

2007-Director of The Tisch Cancer Institute (formerly the Mount Sinai Cancer Institute)

2009-Acting Chief, Division of Hematology and Medical Oncology,

Department of Medicine, Mount Sinai School of Medicine

2008-Lillian and Henry M. Stratton Professor of Cancer Medicine,

Mount Sinai School of Medicine

C. Funding Information:

Past Funding:

3/1/03-2/28/08NIH/NCI Cancer Center Support Grant

5 P30 CA 0160873/1/05 – 2/20/06

Direct Amount: $1,523,65050%

Principal Investigator: Steven J. Burakoff, M.D.

Current

Funding:

NIH

R21AI079695-01 Role of HPK1 in T cell mediated anti-tumor immune response

07/15/2008 Principal Investigator: Steven J. Burakoff, M.D.
06/30/2010 Total amount

Year 1: 125,000

Year 2: 150,000

BIBLIOGRAPHY

Original Reports

1. Martz, E., Burakoff, S.J., and Benacerraf, B.: Interruption of the sequential release of small and large molecules from tumor cells by low temperature during cytolysis mediated by immune T-cells or complement. Proc. Natl. Acad. Sci. USA 1974; 71:177-181.

1. Burakoff, S.J., Martz, E., and Benacerraf, B.: Is the primary complement lesion insufficient for lysis? Failure of cells damaged under osmotic protection to lyse in EDTA or at low temperature after removal of osmotic protection. Clin. Immunol. Immunopath. 1975; 4:108-126.

1. Burakoff, S.J., Germain, R.N., Dorf, M.E., and Benacerraf, B.: Inhibition of cell-mediated cytolysis of trinitrophenyl-derivatized target cells by alloantisera directed to the products of the K and D loci of the H-2 complex. Proc. Natl. Acad. Sci. USA 1976; 73:625-629.

1. Burakoff, S.J., Germain, R.N., and Benacerraf, B.: Cross-reactive lysis of trinitrophenyl (TNP)-derivatized H-2 incompatible target cells by cytolytic T lymphocytes generated against syngeneic TNP spleen cells. J. Exp. Med. 1976; 144:1609-1620.

1. Burakoff, S.J., Dorf, M.E., and Benacerraf, B.: Specificity of rat xenogeneic cell-mediated cytolysis for the products of the K and D loci of the mouse H-2 complex. J. Immunol. 1977; 118:1795-1798.

1. Lemonnier, F., Burakoff, S.J., Germain, R.N., and Benacerraf, B.: Cytolytic thymus-derived lymphocytes specific for allogeneic stimulator cells crossreact with chemically modified syngeneic cells. Proc. Natl. Acad. Sci. USA 1977; 74:1229-1233.

1. Billings, P., Burakoff, S., Dorf, M.E., and Benacerraf, B.: Cytotoxic T lymphocytes specific for I region detererminants do not require interactions with H-2K or D gene products. J. Exp. Med. 1977; 145:1387-1392.

1. Billings, P., Burakoff, S., Dorf, M.E., and Benacerraf, B.: Cytotoxic T lymphocytes induced against allogeneic I-region determinants react with Ia molecules on trinitrophenyl-conjugated syngeneic target cells. J. Exp. Med. 1977; 146:623-628.

1. Burakoff, S.J., Ratnofsky, S.E., and Benacerraf, B.: Mouse cytolytic T lymphocytes induced by xenogeneic rat stimulator cells exhibit specificity for H-2 complex alloantigens. Proc. Natl. Acad. Sci. USA 1977; 74:4572-4576.

1. Mescher, M., Sherman, L., Lemonnier, F., and Burakoff, S.J.: The induction of secondary cytolytic T lymphocytes by solubilized membrane proteins. J. Exp. Med. 1978; 147:946-951.

1. Lemonnier, F., Mescher, M., Sherman, L., and Burakoff, S.J.: The induction of cytolytic T lymphocytes with purified plasma membranes. J. Immunol. 1978; 120:1114-1120.

1. Lemonnier, F., Burakoff, S.J., Mescher, M., Dorf, M.E., and Benacerraf, B.: Inhibition of the induction of cytolytic T lymphocytes with alloantisera directed against H-2K and H-2D gene products. J. Immunol. 1978; 120:1717-1720.

1. Billings, P., Burakoff, S.J., Dorf, M.E., and Benacerraf, B.: Genetic control of cytolytic T-lymphocyte responses. I. Ir gene control of the specificity of cytolytic T lymphocyte responses to trinitrophenyl-modified syngeneic cells. J. Immunol. 1978; 148:341-351.

1. Billings, P., Burakoff, S.J., Dorf, M.E., and Benacerraf, B.: Genetic control of cytolytic T lymphocyte responses. II. The role of the host genotype in parental -> F1radiation chimeras in the control of the specificity of cytolytic T-lymphocyte responses to trinitrophenyl-modified syngeneic cells. J. Exp. Med. 1978; 148:352-359.
2. Sherman, L.A., Burakoff, S.J., and Benacerraf, B.: The induction of cytolytic T lymphocytes with specificity for p-azophenylarsonate coupled syngeneic cells. J. Immunol. 1978; 121:1432-1436.

1. Finberg, R., Burakoff, S.J., Cantor, H., and Benacerraf, B.: Biological significance of alloreactivity: T cells stimulated by Sendai virus-coated syngeneic cells specifically lyse allogeneic target cells. Proc. Natl. Acad. Sci USA 1978; 75:5145-5149.

1. Finberg, R., Mescher, M., and Burakoff, S.J.: The induction of virus-specific cytotoxic T lymphocytes with solubilized viral and membrane proteins. J. Exp. Med. 1978; 148:1620-1627.

1. Burakoff, S.J., Finberg, R., Glimcher, L., Lemonnier, F., Benacerraf, B., and Cantor, H.: The biologic significance of alloreactivity: The ontogeny of T-cell sets specific for alloantigens and modified self antigens. J. Exp. Med. 1978; 148:1414-1422.

1. Engelhard, V.H., Strominger, J.L., Mescher, M., and Burakoff, S.J.: Induction of secondary cytotoxic T lymphocytes by purified HLA-A and HLA-B antigens reconstituted into phospholipid vesicles. Proc. Natl. Acad. Sci. USA 1978; 75:5688-5691.

1. Finberg, R., Weiner, H.L., Fields, B.N., Benacerraf, B., and Burakoff, S.J.: Generation of cytolytic T lymphocytes after retrovirus infection: Role of S1 gene. Proc. Natl. Acad. Sci. USA 1979; 76:442-446.

1. Vadas, M.A., Butterworth, A.E., Burakoff, S., and Sher, A.: Major histocompatibility complex products restrict the adherence of cytolytic T lymphocytes to minor histocompatibility antigens or to trinitrophenyl determinants on schistosomula of Schistosoma mansoni. Proc. Natl. Acad. Sci. USA 1979; 76:1982-1985.

1. Sherman, L., Mescher, M.F., and Burakoff, S.J.: The induction of cytolytic T lymphocytes with syngeneic trinitrophenyl-coupled membranes. J. Immunol. 1979; 123:501-502.

1. Finberg, R., Greene, M.I., Benacerraf, B., and Burakoff, S.J.: The cytolytic T lymphocyte response to trinitrophenyl-modified syngeneic cells. I. Evidence for antigen-specific helper T cells. J. Immunol. 1979; 123:1205-1209.

1. Finberg, R., Burakoff, S.J., Benacerraf, B., and Greene, M.I.: The cytolytic T lymphocyte response to trinitrophenyl-modified syngeneic cells. II. Evidence for antigen-specific suppressor T cells. J. Immunol. 1979; 123:1210-1214.

1. Mescher, M.F., Finberg, R., Sherman, L., and Burakoff, S.J.: Induction of virus-specific H-2 restricted murine CTL by liposomes. In: T and B lLymphocytes: Recognition and Function. Eds, F. Bach, B. Bonavida, and E. Vitteta. Academic Press, New York, 1979; 65:623-632.

1. Sherman, L., Burakoff, S.J., and Mescher, M.F.: Induction of allogeneic cytolytic T lymphocytes by partially purified membrane glycoproteins. Cell. Immunol. 1980; 51:141-150.

1. Finberg, R., Cantor, H., Benacerraf, B., and Burakoff, S.J.: The origins of alloreactivity: Differentiation of pre-killer cells to viral infection results in alloreactive cytolytic T lymphocytes. J. Immunol. 1980; 124:1858-1860.

1. Burakoff, S.J., Engelhard, V.H., Kaufman, J., and Strominger, J.L.: Induction of secondary cytotoxic T lymphocytes by liposomes containing HLA-DR antigens. Nature 1980; 283:495-497.

1. Abbas, A.K., Ratnofsky, S.E., and Burakoff, S.J.: T lymphocyte-mediated suppression of myeloma function in vitro. II. Evidence for regulation of hapten-binding myelomas by syngeneic hapten-specific cytolytic T lymphocytes. J. Exp. Med. 1980; 152:306-323.

1. Brown, A.P., Burakoff, S.J., and Sher, A.: Specificity of alloreactive T lymphocytes that adhere to lung stage schistosomula of Schistosoma mansoni. J. Immunol. 1980; 124:2516-2518.

1. Engelhard, V.H., Kaufman, J.F., Strominger, J.L., and Burakoff, S.J.: Specificity of mouse cytotoxic T lymphocytes stimulated with either HLA-aor -ß or HLA-DR antigens reconstituted into phospholipid vesicles. J. Exp. Med. 1980; 152:54s-64s.

1. Burakoff, S.J., Riccio, J., Billings, P., Benacerraf, B., and Dorf, M.E.: Genetic control of cytolytic T lymphocyte responses. III. The role of K and I region alleles on the specificity of the cytolytic T lymphocyte response to trinitrophenyl-modified syngeneic cells. J. Immunol. 1980; 125:1432-1435.

1. Abbas, A.K., Burakoff, S.J., Gefter, M.L., and Greene, M.I.: T lymphocyte-mediated suppression of myeloma function in vitro. III. Regulation of antibody production in hybrid myeloma cells by T lymphocytes. J. Exp. Med. 1980; 152:969-978.

1. Weinberger, O., Herrmann, S.H., Mescher, M.F., Benacerraf, B., and Burakoff, S.J.: Cellular interactions in the generation of cytolytic T lymphocyte responses: Role of Ia-positive splenic adherent cells in presentation of H-2 antigen. Proc. Natl. Acad Sci. USA 1980; 77:6091-6095.

1. Reiss, C.S., Hemler, M.E., Engelhard, V.H., Mier, J.W., Strominger, J.L., and Burakoff, S.J.: Development and characterization of allospecific long-term human cytolytic T-cell lines. Proc. Natl. Acad. Sci. USA 1980; 77:5432-5436.

1. Burakoff, S.J., Weinberger, O., Herrmann, S.H., and Mescher, M.F.: The use of purified H-2 antigens to define the helper T cell pathway involved in cytolytic T lymphocyte induction. Behring Inst. Mitt. 1980; 67:118-122.

1. Finberg, R., Weiner, H.L., Burakoff, S.J., and Fields, B.N.: Type-specific reovirus antiserum blocks the cytotoxic T cell/target cell interaction: Evidence for the association of the viral hemagglutinin of a nonenveloped virus with the cell surface. Inf. and Imm. 1981; 31:646-649.

1. Burakoff, S.J., Weinberger, O., Herrmann, S.H., and Mescher, M.F.: Cellular interactions in the regulation of the cytolytic T-lymphocyte response: The effect of suboptimal antigen dose. Transplant. Proc. 1981; 13:1039-1043.

1. Weinberger, O., Herrmann, S., Mescher, M.F., Bennacerraf, B., and Burakoff, S.J.: Cellular interactions in the generation of cytolytic T lymphocyte responses. Analysis of the helper T cell pathway. Eur. J. Immunol. 1981; 11:405-411.

1. Weinberger, O., Herrmann, S., Mescher, M.F., Benacerraf, B., and Burakoff, S.J.: Antigen-presenting cell function in induction of helper T cells for cytotoxic T lymphocyte responses: Evidence for antigen processing. Proc. Natl. Acad. Sci. USA 1981; 78:1796-1799.

1. Reiss, C.S., and Burakoff, S.J.: Specificity of the helper T cell for the cytolytic T lymphocyte response to influenza viruses. J. Exp. Med. 1981; 154:541

1. Reiss, C.S., Dorf, M.E., Benacerraf, B., and Burakoff, S.J.: Ir gene control of the cytolytic T cell response to influenza virus. In: Genetic Variation Among Influenza Viruses. Ed., D.P. Nayak. Academic Press, New York, 1981; 449-459.

1. Shapiro, M.E., Burakoff, S.J., Benacerraf, B., and Finberg, R.W.: Ir gene control of the cytotoxic T lymphocyte response to Sendai virus: H-2k mice are low responders to Sendai. J. Immunol. 1981; 127:2571-2574.

1. Gualde, N., Weinberger, O., Ratnofsky, S., Benacerraf, B., and Burakoff, S.J.: In vitro generation of helper T cells and suppressor T cells that regulate the cytolytic T lymphocyte response to trinitrophenyl modified syngeneic cells. Transplantation 1982; 33:422-427.

1. Greene, M.I., Ratnofsky, S., Takaoki, M., Sy, M.S., Burakoff, S.J., and Finberg, R.W.: Antigen-specific suppression of cytotoxic T cell responses: An idiotype-bearing factor regulates the cytotoxic T cell response to azobenzenearsonate-coupled cells. J.Immunol. 1982; 128:1188-1191.

1. Herrmann, S.H., Weinberger, O., Burakoff, S.J., and Mescher, M.F.: Analysis of the two-signal requirement for precursor cytolytic T lymphocyteactivation using H-2Kk in liposomes.